{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:54:27Z","timestamp":1791474867349,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12185-018-2404-8","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T15:37:15Z","timestamp":1517413035000},"page":"405-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Current status and progress of lymphoma management in China"],"prefix":"10.1007","volume":"107","author":[{"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"2404_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2017.04.024","volume":"401","author":"W Chen","year":"2017","unstructured":"Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63\u201371.","journal-title":"Cancer Lett"},{"issue":"2","key":"2404_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2404_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429\u201334.","journal-title":"Am J Clin Pathol"},{"key":"2404_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1746-1596-6-77","volume":"6","author":"QP Yang","year":"2011","unstructured":"Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6:77.","journal-title":"Diagn Pathol."},{"issue":"19","key":"2404_CR5","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2404_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394.","journal-title":"Lancet Oncol."},{"issue":"4","key":"2404_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00277-017-2931-z","volume":"96","author":"TS Chan","year":"2017","unstructured":"Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL. Low-dose pembrolizumab for relapsed\/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol. 2017;96(4):647\u201351.","journal-title":"Ann Hematol"},{"issue":"7","key":"2404_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00277-017-3007-9","volume":"96","author":"YY Hwang","year":"2017","unstructured":"Hwang YY, Khong PL, Kwong YL. Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol. 2017;96(7):1219\u201320.","journal-title":"Ann Hematol"},{"key":"2404_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12885-016-2523-7","volume":"16","author":"J Wu","year":"2016","unstructured":"Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, et al. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. BMC Cancer. 2016;16:537.","journal-title":"BMC Cancer."},{"issue":"6","key":"2404_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00277-011-1375-0","volume":"91","author":"X Li","year":"2012","unstructured":"Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol. 2012;91(6):837\u201345.","journal-title":"Ann Hematol"},{"issue":"22","key":"2404_CR11","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","volume":"31","author":"YH Huang","year":"2013","unstructured":"Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765\u201372.","journal-title":"J Clin Oncol"},{"issue":"23","key":"2404_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2014.15704","volume":"312","author":"H Huang","year":"2014","unstructured":"Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521\u201330.","journal-title":"JAMA"},{"issue":"12","key":"2404_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"9980","key":"2404_CR14","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873\u201383.","journal-title":"Lancet"},{"issue":"7","key":"2404_CR15","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/bcp.13232","volume":"83","author":"J Zhai","year":"2017","unstructured":"Zhai J, Qin Y, Zhu J, Song Y, Shen Z, Du X, et al. Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas. Br J Clin Pharmacol. 2017;83(7):1446\u201356.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2404_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.21147\/j.issn.1000-9604.2016.02.07","volume":"28","author":"L Gui","year":"2016","unstructured":"Gui L, Han X, He X, Song Y, Yao J, Yang J, et al. Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin\u2019s lymphoma. Chin J Cancer Res. 2016;28(2):197\u2013208.","journal-title":"Chin J Cancer Res"},{"issue":"42","key":"2404_CR17","doi-asserted-by":"publisher","first-page":"73168","DOI":"10.18632\/oncotarget.17324","volume":"8","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Wang H, Jin S, Zheng J, Huang M, Tang Y, et al. Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients. Oncotarget. 2017;8(42):73168\u201376.","journal-title":"Oncotarget."},{"issue":"2","key":"2404_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3109\/10428194.2014.920504","volume":"56","author":"H Mo","year":"2015","unstructured":"Mo H, Shi Y, Han X, Zhou S, He X, Liu P, et al. Absolute monocyte count is a prognostic indicator in a patient with diffuse large B-cell lymphoma after autologous peripheral blood stem cell transplant. Leuk Lymphoma. 2015;56(2):515\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2404_CR19","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.4103\/0366-6999.164936","volume":"128","author":"P Zhou","year":"2015","unstructured":"Zhou P, Liu P, Zhou SY, He XH, Han XH, Qin Y, et al. Ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based chemotherapy for mobilization of autologous peripheral blood stem cells in patients with lymphomas. Chin Med J (Engl). 2015;128(18):2498\u2013504.","journal-title":"Chin Med J (Engl)."},{"issue":"11","key":"2404_CR20","first-page":"522","volume":"34","author":"Y Shi","year":"2015","unstructured":"Shi Y, Zhou P, Han X, He X, Zhou S, Liu P, et al. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin\u2019s lymphoma. Chin J Cancer. 2015;34(11):522\u201330.","journal-title":"Chin J Cancer."},{"issue":"3","key":"2404_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/14653240802582067","volume":"11","author":"B Li","year":"2009","unstructured":"Li B, Yang JL, Shi YK, He XH, Han XH, Zhou SY, et al. Etoposide 1.0\u00a0g\/m2 or 1.5\u00a0g\/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity. Cytotherapy. 2009;11(3):362\u201371.","journal-title":"Cytotherapy."},{"issue":"5","key":"2404_CR22","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1111\/ajco.12610","volume":"13","author":"Y Shi","year":"2017","unstructured":"Shi Y, Liu P, Zhou S, Yang J, Han X, He X, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13(5):e423\u20139.","journal-title":"Asia Pac J Clin Oncol."},{"issue":"16","key":"2404_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"8","key":"2404_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor- modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"2404_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti- CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285\u201395.","journal-title":"Mol Ther"},{"issue":"22","key":"2404_CR26","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood.V128.22.LBA-6.LBA-6","volume":"128","author":"SS Neelapu","year":"2016","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, et al. Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1. Blood. 2016;128(22):LBA-6.","journal-title":"Blood."},{"issue":"1","key":"2404_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-017-0535-7","volume":"10","author":"BS Liu","year":"2017","unstructured":"Liu BS, Song YP, Liu DL. Clinical trials of CAR-T cells in China. J Hematol Oncol. 2017;10(1):166.","journal-title":"J Hematol Oncol."},{"issue":"4","key":"2404_CR28","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s12032-012-0184-1","volume":"29","author":"Y Hou","year":"2012","unstructured":"Hou Y, Wang HQ, Ba Y. Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China. Med Oncol. 2012;29(4):2372\u20138.","journal-title":"Med Oncol"},{"issue":"1","key":"2404_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12032-014-0353-5","volume":"32","author":"H Yun","year":"2015","unstructured":"Yun H, Zhang HL, Wang HQ. Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. Med Oncol. 2015;32(1):353.","journal-title":"Med Oncol"},{"issue":"7","key":"2404_CR30","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677\u201384.","journal-title":"Blood"},{"issue":"8","key":"2404_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/2040620717719616","volume":"8","author":"B Fakhri","year":"2017","unstructured":"Fakhri B, Kahl B. Current and emerging treatment options for mantle cell lymphoma. Ther Adv Hematol. 2017;8(8):223\u201334.","journal-title":"Ther Adv Hematol."},{"issue":"9873","key":"2404_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"1","key":"2404_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/leu.2015.180","volume":"30","author":"H Wu","year":"2016","unstructured":"Wu H, Hu C, Wang A. Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016;30(1):173\u201381.","journal-title":"Leukemia"},{"issue":"7","key":"2404_CR34","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/annonc\/mdu142","volume":"25","author":"H Gill","year":"2014","unstructured":"Gill H, Au WY, Cheung WW, Lee EY, Kwong YL. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol. 2014;25(7):1391\u20137.","journal-title":"Ann Oncol"},{"issue":"25","key":"2404_CR35","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"key":"2404_CR36","doi-asserted-by":"publisher","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.","journal-title":"ISRN Hematol"},{"issue":"1","key":"2404_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12185-013-1465-y","volume":"99","author":"L Gui","year":"2014","unstructured":"Gui L, Shi YK, He XH, Lei YH, Zhang HZ, Han XH, et al. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. Int J Hematol. 2014;99(1):69\u201378.","journal-title":"Int J Hematol"},{"issue":"8","key":"2404_CR38","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.bbmt.2017.04.021","volume":"23","author":"H Huang","year":"2017","unstructured":"Huang H, Jiang Y, Wang Q, Guo L, Jin Z, Fu Z, et al. Outcome of allogeneic and autologous hematopoietic cell transplantation for high-risk peripheral T cell lymphomas: a retrospective analysis from a Chinese center. Biol Blood Marrow Transplant. 2017;23(8):1393\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2404_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0300060516676725","volume":"45","author":"X Han","year":"2017","unstructured":"Han X, Zhang W, Zhou D, Ruan J, Duan M, Zhu T, et al. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: a single-centre experience. J Int Med Res. 2017;45(1):290\u2013302.","journal-title":"J Int Med Res"},{"issue":"3","key":"2404_CR40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.4103\/0973-1482.189235","volume":"12","author":"J Bo","year":"2016","unstructured":"Bo J, Zhao Y, Zhang S, Hua W, Wang S, Gao C, et al. Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma. J Cancer Res Ther. 2016;12(3):1189\u201397.","journal-title":"J Cancer Res Ther."},{"issue":"5","key":"2404_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14763","volume":"178","author":"L Li","year":"2017","unstructured":"Li L, Duan W, Zhang L, Li X, Fu X, Wang X, et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol. 2017;178(5):772\u201380.","journal-title":"Br J Haematol"},{"key":"2404_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/OTT.S117007","volume":"10","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Cao J, Xue K, Liu X, Ji D, Guo Y, et al. Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. Onco Targets Ther. 2016;10:145\u201351.","journal-title":"Onco Targets Ther."},{"issue":"3","key":"2404_CR43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5582\/irdr.2016.01024","volume":"5","author":"X Lu","year":"2016","unstructured":"Lu X, Ning Z, Li Z, Cao H, Wang X. Development of Chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis Res. 2016;5(3):185\u201391.","journal-title":"Intractable Rare Dis Res."},{"issue":"4","key":"2404_CR44","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2404_CR45","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371.","journal-title":"Ann Oncol"},{"issue":"1","key":"2404_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T-cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.","journal-title":"J Hematol Oncol."},{"issue":"9","key":"2404_CR47","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2404_CR48","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"issue":"23","key":"2404_CR49","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2404_CR50","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase IIstudy. J Clin Oncol. 2012;30(18):2190\u20136.","journal-title":"J Clin Oncol"},{"issue":"28","key":"2404_CR51","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137\u201343.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2404_CR52","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Thieblemont C, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol. 2015;2(4):e160\u20135.","journal-title":"Lancet Haematol."},{"issue":"4","key":"2404_CR53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.13855","volume":"172","author":"RH Advani","year":"2016","unstructured":"Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172(4):535\u201344.","journal-title":"Br J Haematol"},{"key":"2404_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-016-0368-9","volume":"10","author":"Y Huang","year":"2017","unstructured":"Huang Y, Jia B, Jiang S, Zhou S, Yang J, Liu P, et al. Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK\/T cell lymphoma. J Hematol Oncol. 2017;10:7.","journal-title":"J Hematol Oncol."},{"issue":"7","key":"2404_CR55","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/leu.2015.44","volume":"29","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK\/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29(7):1571\u20137.","journal-title":"Leukemia"},{"issue":"9","key":"2404_CR56","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47(9):1061\u20136.","journal-title":"Nat Genet"},{"issue":"8","key":"2404_CR57","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1182\/blood-2008-05-160176","volume":"112","author":"YX Li","year":"2008","unstructured":"Li YX, Fang H, Liu QF, Lu J, Qi SN, Wang H, et al. Clinical features and treatment outcome of nasal-type NK\/T-cell lymphoma of Waldeyer ring. Blood. 2008;112(8):3057\u201364.","journal-title":"Blood"},{"issue":"1","key":"2404_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","volume":"24","author":"YX Li","year":"2006","unstructured":"Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol. 2006;24(1):181\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2404_CR59","doi-asserted-by":"publisher","first-page":"3294-01","DOI":"10.1002\/cncr.26629","volume":"118","author":"M Jiang","year":"2012","unstructured":"Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, et al. Phase 2 trial of \u201csandwich\u201d l-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma. Cancer. 2012;118(13):3294-01.","journal-title":"Cancer"},{"issue":"2","key":"2404_CR60","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/cncr.27752","volume":"119","author":"L Wang","year":"2013","unstructured":"Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, et al. First-line combination of gemcitabine, oxaliplatin, and l-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma. Cancer. 2013;119(2):348\u201355.","journal-title":"Cancer"},{"key":"2404_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2016.05.004","volume":"47","author":"XM Jing","year":"2016","unstructured":"Jing XM, Zhang ZH, Wu P, Zhang SC, Ren YR, Xiong ZJ, et al. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)\/T cell lymphoma. Leuk Res. 2016;47:26\u201331.","journal-title":"Leuk Res"},{"issue":"30","key":"2404_CR62","doi-asserted-by":"publisher","first-page":"50155","DOI":"10.18632\/oncotarget.16334","volume":"8","author":"M Jiang","year":"2017","unstructured":"Jiang M, Zhang L, Xie L, Zhang H, Jiang Y, Liu WP, et al. A phase II prospective study of the \u201cSandwich\u201d protocol, l-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I\/II stage, nasal type, extranodal natural killer\/T-cell lymphoma. Oncotarget. 2017;8(30):50155\u201363.","journal-title":"Oncotarget."},{"issue":"7","key":"2404_CR63","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3109\/10428194.2015.1108415","volume":"57","author":"LH Dong","year":"2016","unstructured":"Dong LH, Zhang LJ, Wang WJ, Lei W, Sun X, Du JW, et al. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK\/T-cell lymphoma. Leuk Lymphoma. 2016;57(7):1600\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2404_CR64","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00277-017-3046-2","volume":"96","author":"Y Huang","year":"2017","unstructured":"Huang Y, Yang J, Liu P, Zhou S, Gui L, He X, et al. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I\/II extranodal natural killer\/T cell lymphoma, nasal type. Ann Hematol. 2017;96(9):1477\u201383.","journal-title":"Ann Hematol"},{"issue":"33","key":"2404_CR65","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410\u20136.","journal-title":"J Clin Oncol."},{"issue":"4","key":"2404_CR66","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s12032-013-0720-7","volume":"30","author":"L Yang","year":"2013","unstructured":"Yang L, Liu H, Xu XH, Wang XF, Huang HM, Shi WY, et al. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)\/T cell lymphoma, nasal type. Med Oncol. 2013;30(4):720.","journal-title":"Med Oncol"},{"issue":"21","key":"2404_CR67","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-16-0153","volume":"22","author":"X Li","year":"2016","unstructured":"Li X, Cui Y, Sun Z, Zhang L, Li L, Wang X, et al. DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016;22(21):5223\u20138.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2404_CR68","doi-asserted-by":"crossref","first-page":"29092","DOI":"10.18632\/oncotarget.8647","volume":"7","author":"JH Wang","year":"2016","unstructured":"Wang JH, Wang L, Liu CC, Xia ZJ, Huang HQ, Lin TY, et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma. Oncotarget. 2016;7(20):29092\u2013101.","journal-title":"Oncotarget."},{"key":"2404_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2325","author":"R Liang","year":"2016","unstructured":"Liang R, Gao GX, Chen JP, Wang JS, Wang XM, Zeng Y, et al. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer\/T-cell lymphoma, nasal type: a multicenter trial in Northwest China. Hematol Oncol. 2016. https:\/\/doi.org\/10.1002\/hon.2325 .","journal-title":"Hematol Oncol."},{"issue":"7","key":"2404_CR70","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3109\/10428194.2014.999323","volume":"56","author":"JL Yang","year":"2015","unstructured":"Yang JL, Shi YK, Dong M, Dong M, Zhang C, Liu P, et al. A preliminary study of the safety and efficacy of DIMG chemotherapy for natural killer\/T-cell lymphoma. Leuk Lymphoma. 2015;56(7):2218\u201321.","journal-title":"Leuk Lymphoma"},{"key":"2404_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2324-z","author":"J Wang","year":"2017","unstructured":"Wang J, Wei L, Ye J, Yang L, Li X, Cong J, et al. Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. Int J Hematol. 2017. https:\/\/doi.org\/10.1007\/s12185-017-2324-z .","journal-title":"Int J Hematol"},{"issue":"17","key":"2404_CR72","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437\u201342.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2404-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2404-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2404-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:53:42Z","timestamp":1693511622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2404-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2404"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2404-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"5 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}